TheranosticTrials.org

Clinical Trial · NCT01916122

Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status

Overview

These are tumors which expresses estrogen receptors. Estrogen receptors are found within breast cancer cells and are an important marker of which medicines may best treat a breast cancer. This study is being performed to imaging the amount of estrogen receptors expressed in the tumor. A research agent named 16α-18F-fluoroestradiol (FES) finds estrogen receptors and binds to them. Then tumors with estrogen receptors can be imaged by a PET/CT scanner, a machine that can take pictures of where the FES is and how much FES is present. The results of this study may help researchers know whether FES can be used to monitor changes in estrogen receptors in tumors during treatment.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

Early Phase 1

Contacts

Randy Yeh, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01916122

Drug / Compound

fluoroestradiol

Isotope(s):
Target(s):
  • Estrogen Receptor
Ligand Class: Small Molecules

Eligibility

Inclusion

  • ECOG performance status of 0-2.
  • Patients who are to be treated with clinically approved or experimental regimens where ER has an important role
  • Patients with histologic/immunochemical proof of ER+ primary or metastatic malignancy (positive staining in ≥ 1% of cells by immunohistochemistry).

Exclusion

  • Serum creatinine \> 1.5 times upper limit of normal.
  • Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia)
  • Total serum bilirubin \> 1.5 times upper limit of normal (abnormal hepatic metabolism may interfere with FES hepatic excretion). Increased serum bilirubin due to Gilbert's syndrome is permitted.